Atara Biotherapeutics Inc

ATRA

$16.07

+24.19% (1 year change)

Avg closing price

Price range

Market Cap

$1.34 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

-

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$0.00

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

-

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

News

Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results, Misses Expectations By $0.22 EPS

Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results, Misses Expectations By $0.22 EPS

Atara Biotherapeutics (NASDAQ:ATRA) announced its quarterly earnings data on Sunday. The biotechnology company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estim...

Transcript Daily Transcript Daily, 6 days ago
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transform...

Business Wire Business Wire, 7 days ago
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transforma...

Business Wire Business Wire, 18 days ago